MedTrace Logo

Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)

NCT06075368 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 757

Last updated 2026-02-11

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of the GENOSS SES in patients with acute coronary syndrome (ACS) in real-world pratice.

Conditions

  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention

Interventions

DEVICE

GENOSS Sirolimus Eluting Coronary Stent System

The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.

Sponsors & Collaborators

  • Genoss Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06075368 on ClinicalTrials.gov